Skip to main content
Clinical Trials/NCT03346629
NCT03346629
Completed
Phase 4

Evaluating the Safety, Acceptability and Feasibility of an Outpatient "Day Procedure" Service Documenting the Roles of Health Workers in the Provision of Medical Abortion at 13-18 Weeks Gestation

Gynuity Health Projects3 sites in 1 country230 target enrollmentDecember 1, 2017

Overview

Phase
Phase 4
Intervention
Mifepristone + Misoprostol
Conditions
Abortion in Second Trimester
Sponsor
Gynuity Health Projects
Enrollment
230
Locations
3
Primary Endpoint
Successful medical abortion
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

This study seeks to evaluate the safety, acceptability and feasibility of an outpatient "day procedure" for medical abortion at 13-18 weeks gestation. The study regimen will consist of a single dose of 200 mg mifepristone to be taken orally either at home or at the hospital, followed approximately 24 - 48 hours later with administration of 400 mcg misoprostol. Repeat doses of 400 mcg (two tablets) of misoprostol will be administered buccally every three hours until the abortion is achieved.

Registry
clinicaltrials.gov
Start Date
December 1, 2017
End Date
December 31, 2018
Last Updated
7 years ago
Study Type
Interventional
Study Design
Single Group
Sex
Female

Investigators

Sponsor
Gynuity Health Projects
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Have an ongoing pregnancy of 13-18 weeks gestation
  • Meet legal criteria to obtain an abortion at 13-18 weeks gestation (legal criteria include pregnancy resulting from rape or incest, fetal malformation and/or if the pregnancy affects the physical or mental health of the woman)
  • Has access to a phone where she can be reached at the 2-week follow-up
  • Be willing to follow study procedures

Exclusion Criteria

  • Known allergy to mifepristone or misoprostol/prostaglandin or other contraindications to the use of mifepristone or misoprostol
  • Any contraindications to vaginal delivery
  • More than one prior cesarean delivery
  • Living more than 2 hours away from the hospital

Arms & Interventions

Mifepristone + Misoprostol

Intervention: 200mg mifepristone followed 24-48 h later with 400mcg misoprostol (repeat Q3)

Intervention: Mifepristone + Misoprostol

Outcomes

Primary Outcomes

Successful medical abortion

Time Frame: 0 - 48 hours after first dose of mifepristone

Proportion of women who have a successful medical abortion without recourse to surgical intervention and return home on the same day as misoprostol induction

Secondary Outcomes

  • Total dose of misoprostol(0 - 48 hours after first misoprostol dose)
  • Safety - Proportion of participants who experience at least one of the following: extramural delivery, hemorrhage requiring transfusion, infection, uterine rupture, prolonged hospitalization, any complications(2 weeks after initial visit)
  • Hospital admission time(Within 0 - 48 hours after the second dose of misoprostol)
  • Induction-to-abortion interval(0 - 48 hours after first misoprostol dose)
  • Tasks performed by certified staff(0 - 72 hours after receipt of mifepristone)
  • Side Effects(0 - 48 hours after first dose of misoprostol)
  • Initiation-to-abortion interval(0 - 72 hours after receipt of mifepristone)

Study Sites (3)

Loading locations...

Similar Trials